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99* Roscovitine: a novel corrector for the functional rescue of
F508del-CFTR protein
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The most common mutation in Cystic Fibrosis, F508del, causes defects in trafﬁck-
ing, channel gating and endocytosis of the CFTR (CF Transmembrane conductance
Regulator) protein. We have previously developed an automatic assay to identify
agents, termed correctors, directed at repairing these defects. This study shows the
identiﬁcation from our screening of a novel corrector, roscovitine, able to restore the
membrane localization and functionality of F508del-CFTR protein on the human
airway epithelial CF cell line JME/CF15.
We found that roscovitine corrected F508del-CFTR with an EC50 of 56mM.
Moreover, biochemical analysis and immunoﬂuorescence imaging conﬁrmed the
restoration of a mature F508del-CFTR at the cell surface. To pinpoint the molecular
mechanism of roscovitine, we realized competition studies between roscovitine and
inhibitors of the endoplasmic reticulum quality control (ERQC). No potentiation of
roscovitine correction occured after co-treatment by roscovitine and the degradation
inhibitor MG132. Only a small potentiation was obtained after co-treatment by
roscovitine and thapsigargin which inhibits interaction between CFTR and calnexin,
a Ca2+-dependent ER chaperone. Additional studies showed that roscovitine stim-
ulates an intracellular Ca2+ increase, consecutive of the ER emptying. Moreover
a Ca2+-independent inhibition of proteasome activity (~50%) in CF15 cells was
observed after a roscovitine treatment.
We conclude from the present study that roscovitine restores the abnormal trafﬁck-
ing of F508del-CFTR via a Ca2+-dependent and a Ca2+-independent mechanisms
of action allowing disturbance of the ability of the ERQC to interact and to degrade
F508del-CFTR proteins.
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Sinusitis is common in patients with CF. Current treatments do not target defective
ion transport, which may contribute to the pathogenesis of chronic sinus disease
in CF. Denufosol is a novel inhaled P2Y2 receptor agonist designed to treat
the ion channel defect in CF lung disease by stimulating an alternative chloride
channel (calcium-activated chloride channel), water and mucin secretion and by
increasing cilia beat frequency on airway epithelia to enhance mucociliary clearance.
TIGER-1 (Study 08–108) was a 6-month placebo-controlled, double-blind, multi-
center Phase 3 study comparing the effects of denufosol and placebo (normal saline)
administered three-1times-daily via jet nebulizer on lung function and other param-
eters in 352 patients 5 years of age with CF. In addition to a signiﬁcant beneﬁt
in FEV1 at the primary efﬁcacy endpoint, there were signiﬁcantly fewer reports of
adverse events (AEs) typically associated with sinusitis. Among the most commonly
reported AEs ( 10% in any group) during the 6-month placebo-controlled study,
signiﬁcantly fewer events were reported by patients who administered denufosol
compared to placebo with respect to sinusitis (10% vs 18%; p = 0.030), headache
(11% vs 25%; p = 0.001) and rhinorrhea (10% vs 18%; p = 0.046). Post-nasal drip
AEs were also diminished for denufosol-treated patients (2% vs 5%; p = 0.085).
Sinus congestion occurred more frequently for denufosol-treated patients (7% vs
3%; p = 0.088). These data provide preliminary evidence that denufosol may have
the potential to reduce the occurrence of sinus-related complaints in CF patients,
presumably due to activity on the sinus and nasal epithelial surface.
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The relationship between pulmonary exacerbations (PEx) and lung function decline
in cystic ﬁbrosis (CF) is not completely understood. The purpose of this research
was to describe changes in lung function by occurrence of PEx among CF patients
participating in a randomized, double-blind, placebo-controlled trial of denufosol. A
total of 352 patients 5 years of age in the US and Canada with a screening FEV1%
predicted 75% were randomized to receive either denufosol or placebo three times
per day for 24 weeks. Lung function was measured using central spirometry at 6
study visits. PEx, deﬁned as reporting at least 4 out of 12 Fuchs’ criteria regardless
of treatment, were tracked during the study. Differences in the change from baseline
(CFB) FEV1 with respect to treatment and exacerbation were tested via analysis of
covariance (ANCOVA) models. Overall, the adjusted mean CFB FEV1 was −34mL
for patients with PEx (n = 80) vs. +43mL for patients free from PEx (n = 272;
p = 0.006). Among patients who experienced a PEx, those treated with denufusol
(n = 47) had an adjusted mean CFB of +2mL in FEV1 vs. −99mL for those treated
with placebo (n = 33; p = 0.06). PEx in both treatment groups were similar relative
to the demographics of patients, duration of PEx, time to PEx, and treatment with
IV antibiotics. These data suggest loss in lung function is greater in patients who
experience PEx than in patients PEx-free. In addition, denufosol may attenuate the
effects of PEx on lung function.
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Increased ENaC-mediated airway Na+ absorption is a characteristic abnormality
in the pathogenesis of cystic ﬁbrosis (CF) lung disease and causes CF-like lung
disease in mice. We recently demonstrated that preventive, but not late, ENaC
inhibition by its classical blocker amiloride reduced mortality and morbidity of CF-
like lung disease in bENaC-transgenic (bENaC-Tg) mice (Zhou Z. et al, 2008).
We hypothesized that the ineffectiveness of late amiloride therapy was due to
(i) the low potency and rapid absorption of amiloride from airway surfaces, or
(ii) irreversible lung pathology. To distinguish between these possibilities, we used
a novel, highly potent and long acting ENaC blocker, P643 (Parion Sciences),
shown to be 35−60-fold more potent and ~5-fold longer acting than amiloride
in vitro, and tested the therapeutic beneﬁts of P643 on CF-like lung disease in
mice. Newborn or 4-week old bENaC-Tg and wild-type mice were treated by
intrapulmonary administration of P643 or vehicle alone for 2 weeks. Subsequently,
mice were euthanized, bronchoalveolar lavage performed, and lungs processed for
histology. We demonstrate that P643 is an effective preventive therapy, and that late
intervention with P643 signiﬁcantly reduced airway mucus obstruction, neutrophilic
inﬂammation and epithelial remodeling in established lung disease in bENaC-Tg
mice. These results suggest that long acting ENaC blockers may have therapeutic
effects in CF patients with chronic lung disease.
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